Vernakalant versus procainamide for rapid cardioversion of patients with acute atrial fibrillation (RAFF4): randomised clinical trial.

Stiell IG, Taljaard M, Eagles D, Yadav K, Vadeboncoeur A, Hohl CM, Archambault PM, Birnie D, Brown E, Campbell SG, Chen Y, Clement CM, Cournoyer A, de Wit K, Emond M, Macle L, McRae AD, Mercier E, Morris J, Mohamad G, Nemnom MJ, Nicholls SG, Pare D, Parkash R, Sivilotti M, Thavorn K, Perry JJ

Open source

DOI: 10.1136/bmj-2025-085632
Published: 2025 Nov 11
Container: BMJ (Clinical research ed.)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/bmj-2025-085632,
  title = {Vernakalant versus procainamide for rapid cardioversion of patients with acute atrial fibrillation (RAFF4): randomised clinical trial.},
  author = {Stiell IG and Taljaard M and Eagles D and Yadav K and Vadeboncoeur A and Hohl CM and Archambault PM and Birnie D and Brown E and Campbell SG and Chen Y and Clement CM and Cournoyer A and de Wit K and Emond M and Macle L and McRae AD and Mercier E and Morris J and Mohamad G and Nemnom MJ and Nicholls SG and Pare D and Parkash R and Sivilotti M and Thavorn K and Perry JJ},
  year = {2025},
  journal = {BMJ (Clinical research ed.)},
  doi = {10.1136/bmj-2025-085632},
  url = {https://doi.org/10.1136/bmj-2025-085632}
}

RIS

TY  - JOUR
TI  - Vernakalant versus procainamide for rapid cardioversion of patients with acute atrial fibrillation (RAFF4): randomised clinical trial.
AU  - Stiell IG
AU  - Taljaard M
AU  - Eagles D
AU  - Yadav K
AU  - Vadeboncoeur A
AU  - Hohl CM
AU  - Archambault PM
AU  - Birnie D
AU  - Brown E
AU  - Campbell SG
AU  - Chen Y
AU  - Clement CM
AU  - Cournoyer A
AU  - de Wit K
AU  - Emond M
AU  - Macle L
AU  - McRae AD
AU  - Mercier E
AU  - Morris J
AU  - Mohamad G
AU  - Nemnom MJ
AU  - Nicholls SG
AU  - Pare D
AU  - Parkash R
AU  - Sivilotti M
AU  - Thavorn K
AU  - Perry JJ
PY  - 2025
JO  - BMJ (Clinical research ed.)
DO  - 10.1136/bmj-2025-085632
UR  - https://doi.org/10.1136/bmj-2025-085632
ER  -

APA

IG, S., M, T., D, E., K, Y., A, V., CM, H., PM, A., D, B., E, B., SG, C., Y, C., CM, C., A, C., K, D. W., M, E., L, M., AD, M., E, M., J, M., G, M., MJ, N., SG, N., D, P., R, P., M, S., K, T., & JJ, P. (2025). Vernakalant versus procainamide for rapid cardioversion of patients with acute atrial fibrillation (RAFF4): randomised clinical trial.. BMJ (Clinical research ed.). https://doi.org/10.1136/bmj-2025-085632

Source records

pubmed · retrieved 2026-09-26T22:39:53.693Z